Vulvar And Vaginal Atrophy Therapy Market
SHARE
PUBLISHED: 2022 ID: SMRC21840
SHARE

Vulvar and Vaginal Atrophy Therapy Market Forecasts to 2028 - Global Analysis By Diagnosis (Urine Test, Pelvic Examination, Acid Balance Test), Treatment (Selective Estrogen Receptor Modulators, Non Hormonal Therapy, Laser Therapy) and By Geography

4.3 (96 reviews)
4.3 (96 reviews)
Published: 2022 ID: SMRC21840

This report covers the impact of COVID-19 on this global market

Years Covered

2020-2028

CAGR (2022 - 2028)

12%

Regions Covered

North America, Europe, Asia Pacific, South America, and Middle East & Africa

Countries Covered

US, Canada, Mexico, Germany, UK, Italy, France, Spain, Japan, China, India, Australia, New Zealand, South Korea, Rest of Asia Pacific, South America, Argentina, Brazil, Chile, Middle East & Africa, Saudi Arabia, UAE, Qatar, and South Africa

Largest Market

Europe

Fastest Growing Market

Asia Pacific


According to Stratistics MRC, the Global Vulvar and Vaginal Atrophy Therapy Market is growing at a CAGR of 12% during the forecast period. Vulvar and vaginal atrophy (VVA) is a common condition that impacts women after menopause, nevertheless, it is not always symptomatic. The vaginal epithelium thins, vaginal blood flow declines, and vaginal lubrication decrease as estrogen levels decline throughout menopause.

According to the National Institute of Health, ~1.3 million women in the United States enter menopause each year. The age of menopause begins mostly between 51 and 52 years of age. However, approximately 5% of women worldwide experience early menopause between the ages of 40 and 45, and 1% experience premature menopause, i.e., before the age of 40, due to sex chromosomal abnormalities, resulting in permanent ovarian failure. According to the World Health Organization (WHO), in 2020, 2.3 million women were diagnosed with breast cancer worldwide. On the other hand, according to the National Cancer Institute, as of 2022, uterine cancer represents 3.4% of all new cancer cases in the United States.



Market Dynamics:

Driver:

Growing occurrences of breast cancer and uterine cancer in women

Due to rising occurrences of breast cancer and uterine cancer in women is one of the majot factors driving the market growth. Breast cancer has been found to affect the body’s hormones. In women, about 67%-80% of breast cancer cases are estrogen receptor (ER) positive, while in men, around 90% and 80% are estrogen receptor (ER) and progesterone receptor (PR) positive, respectively.

Restraint:

Recurring infections

Due to vulvar and vaginal atrophy therapy few experience frequent vaginal infections. Changes in the pH level of vagina may cause bacterial or fungal infections. Hence recurring infection found in the people taking this therapy is one of the restraint factors hampering the market growth

Opportunity:

Growing lifestyle related diseases in women

Lifestyle diseases, related with physical inactivity and poor diet quality, pose a significant health burden. Gestational diabetes mellitus (GDM), type 2 diabetes (DM2), and polycystic ovary syndrome (PCOS) are a few of the lifestyle-related diseases that affect women. According to the Centers for Disease Control and Prevention, PCOS is one of the most common causes of female infertility, affecting 6% to 12% (up to 5 million) of US women of reproductive age as of 2020. Certain lifestyle disorders, such as depression, insomnia, and weight gain, are also common among a woman which in turn creates opportunity for the market growth.

Threat:

Urinary tract-connected problems

Some of the female may experience urinary tract-related issues owing to vaginal atrophy. Burning sensation, frequent urge to urinate is often a complication of untreated vaginal atrophy. No or very little sexual activity can put at the risk of developing vaginal atrophy. Sexual activity is crucial to increase blood flow in reproductive parts and enhances the elasticity of vagina is one of the factor threaten the market growth.

Impact of Covid- 19

The impact of COVID-19 on the market is predicted to be significant just like any other sector. The industry has witnessed a negative impact as most of the populations across the globe deferred this therapy due to restrictions on transportation and owing to the fear of viral infection. Additionally, as per the research article published in Aesthetic Plastic Surgery, 2020, the financial constraints and the inability to pay for procedures in the future by the patients have led to a downtrend in market globally.

The Selective Estrogen Receptor Modulators segment is expected to be the largest during the forecast period

The Selective Estrogen Receptor Modulators segment is expected to be the largest during the forecast period as it is a class of drugs that act on the estrogen receptor. Selective estrogen receptor modulators (SERMs), also known as estrogen receptor agonist/antagonists. A characteristic that distinguishes these substances from pure ER agonists and antagonists (that is, full agonists and silent antagonists) is that their action is different in various tissues, thereby granting the possibility to selectively inhibit or stimulate estrogen-like action in various tissues. Selective estrogen receptor modulators (SERMs) are a group of medications that affect estrogen. They can block estrogen in some areas of body, but help it in others. SERMs can be used to treat a variety of health conditions, such as breast cancer and osteoporosis.

The Vaginal Dryness segment is expected to have the highest CAGR during the forecast period

The Vaginal Dryness segment is expected to have the highest CAGR during the forecast period. As, vulvar and vaginal atrophy therapy can alleviate dryness, irritation, and painful intercourse. It may even relieve other symptoms of menopause, such as hot flashes, night sweats, and sleep disturbances. Women undergoing this therapy typically see results after four to six weeks. The latest treatment for vaginal atrophy is MonaLisa Touch. This laser treatment helps to restore vaginal tissues to their normal, pre-menopause thickness, elasticity and level of moisture.

Region with highest share:

Europe is projected to have the highest CAGR over the forecast period, owing to the growing demand for vulvar vaginal atrophy therapy (VVA). Other important drivers supporting the growth of the market include a growing number of surgeons in the province, consumer buying power, well-established health care infrastructure, and research activity in the industry. Additionally, rising awareness of vulvar and vaginal atrophy therapy (VVA) and increasing acceptance of modern technologies are likely to boost demand in this province.

Region with highest CAGR:

Asia Pacific is projected to hold the largest market share during the forecast period. The factor attributed to the market growth is the rising number of patients with VVA symptoms, increasing awareness on VVA therapy, and growing healthcare spending to dominate the global market for vulvar and vaginal atrophy therapy in the Asia Pacific. Furthermore, growing R&D activities in the field of vaginal regulation along with acceptance of numerous growth and development strategies are predictable to drive the market.



Key players in the market

Some of the key players profiled in the Vulvar and Vaginal Atrophy Therapy Market include Viveve, Inc., VenusConcept, ThermiGen LLC, TherapeuticsMD, Inc., Lutronic, Hologic, Fotona, BTL Group of Companies, Almirall, Alma Lasers, Sinclair.

Key Developments:

In February 2021: Viveve Medical Inc. announced that it had obtained the South Korean patent No. 10-2197234 titled, Vaginal Remodeling Device and Method, for its novel dual-energy technology device, thus expanding the company's intellectual property portfolio in the South Korean market.

In June 2022: Sinclair launched the V-VR handpiece for a non-invasive, pain-free vaginal rejuvenation treatment. The device is a clinically proven solution with co-polar RF for vaginal rejuvenation.

Diagnoses Covered:
• Urine Test
• Pelvic Examination
• Acid Balance Test

Treatments Covered:
• Selective Estrogen Receptor Modulators
• Non Hormonal Therapy
• Laser Therapy
• Hormonal Therapy

Indications Covered:
• Vaginal Dryness
• Vaginal Burning
• Vaginal Discharge
• Genital Itching
• Recurrent Urinary Tract Infections
• Urinary Incontinence
• Light Bleeding After Intercourse
• Discomfort with Intercourse
• Decreased Vaginal Lubrication During Sexual Activity
• Shortening and Tightening of the Vaginal Canal
• Burning Sensation in the Vagina
• Dyspareunia
• Urinary Tract Infection

End Users Covered:
• Ambulatory Surgical Centers
• Specialty Clinics

Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2020, 2021, 2022, 2025 and 2028
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions

3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 End User Analysis
3.7 Emerging Markets
3.8 Impact of Covid-19

4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Vulvar and Vaginal Atrophy Therapy Market, By Diagnosis
5.1 Introduction
5.2 Urine Test
5.3 Pelvic Examination
5.4 Acid Balance Test

6 Global Vulvar and Vaginal Atrophy Therapy Market, By Treatment
6.1 Introduction
6.2 Selective Estrogen Receptor Modulators
6.3 Non Hormonal Therapy
6.4 Laser Therapy
6.5 Hormonal Therapy

7 Global Vulvar and Vaginal Atrophy Therapy Market, By Indication
7.1 Introduction
7.2 Vaginal Dryness
7.3 Vaginal Burning
7.4 Vaginal Discharge
7.5 Genital Itching
7.6 Recurrent Urinary Tract Infections
7.7 Urinary Incontinence
7.8 Light Bleeding After Intercourse
7.9 Discomfort with Intercourse
7.10 Decreased Vaginal Lubrication During Sexual Activity
7.11 Shortening and Tightening of the Vaginal Canal
7.12 Burning Sensation in the Vagina
7.13 Dyspareunia
7.14 Urinary Tract Infection

8 Global Vulvar and Vaginal Atrophy Therapy Market, By End User
8.1 Hospitals
8.2 Ambulatory Surgical Centers
8.3 Specialty Clinics

9 Global Vulvar and Vaginal Atrophy Therapy Market, By Geography
9.1 Introduction
9.2 North America
9.2.1 US
9.2.2 Canada
9.2.3 Mexico
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 Italy
9.3.4 France
9.3.5 Spain
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 New Zealand
9.4.6 South Korea
9.4.7 Rest of Asia Pacific
9.5 South America
9.5.1 Argentina
9.5.2 Brazil
9.5.3 Chile
9.5.4 Rest of South America
9.6 Middle East & Africa
9.6.1 Saudi Arabia
9.6.2 UAE
9.6.3 Qatar
9.6.4 South Africa
9.6.5 Rest of Middle East & Africa

10 Key Developments
10.1 Agreements, Partnerships, Collaborations and Joint Ventures
10.2 Acquisitions & Mergers
10.3 New Product Launch
10.4 Expansions
10.5 Other Key Strategies

11 Company Profiling
11.1 Viveve, Inc.
11.2 VenusConcept
11.3 ThermiGen LLC
11.4 TherapeuticsMD, Inc.
11.5 Lutronic
11.6 Hologic
11.7 Fotona
11.8 BTL Group of Companies
11.9 Almirall
11.10 Alma Lasers
11.11 Sinclair

List of Tables
1 Global Vulvar and Vaginal Atrophy Therapy Market Outlook, By Region (2020-2028) (US $MN)
2 Global Vulvar and Vaginal Atrophy Therapy Market Outlook, By Diagnosis (2020-2028) (US $MN)
3 Global Vulvar and Vaginal Atrophy Therapy Market Outlook, By Urine Test (2020-2028) (US $MN)
4 Global Vulvar and Vaginal Atrophy Therapy Market Outlook, By Pelvic Examination (2020-2028) (US $MN)
5 Global Vulvar and Vaginal Atrophy Therapy Market Outlook, By Acid Balance Test (2020-2028) (US $MN)
6 Global Vulvar and Vaginal Atrophy Therapy Market Outlook, By Treatment (2020-2028) (US $MN)
7 Global Vulvar and Vaginal Atrophy Therapy Market Outlook, By Selective Estrogen Receptor Modulators (2020-2028) (US $MN)
8 Global Vulvar and Vaginal Atrophy Therapy Market Outlook, By Non Hormonal Therapy (2020-2028) (US $MN)
9 Global Vulvar and Vaginal Atrophy Therapy Market Outlook, By Laser Therapy (2020-2028) (US $MN)
10 Global Vulvar and Vaginal Atrophy Therapy Market Outlook, By Hormonal Therapy (2020-2028) (US $MN)
11 Global Vulvar and Vaginal Atrophy Therapy Market Outlook, By Indication (2020-2028) (US $MN)
12 Global Vulvar and Vaginal Atrophy Therapy Market Outlook, By Vaginal Dryness (2020-2028) (US $MN)
13 Global Vulvar and Vaginal Atrophy Therapy Market Outlook, By Vaginal Burning (2020-2028) (US $MN)
14 Global Vulvar and Vaginal Atrophy Therapy Market Outlook, By Vaginal Discharge (2020-2028) (US $MN)
15 Global Vulvar and Vaginal Atrophy Therapy Market Outlook, By Genital Itching (2020-2028) (US $MN)
16 Global Vulvar and Vaginal Atrophy Therapy Market Outlook, By Recurrent Urinary Tract Infections (2020-2028) (US $MN)
17 Global Vulvar and Vaginal Atrophy Therapy Market Outlook, By Urinary Incontinence (2020-2028) (US $MN)
18 Global Vulvar and Vaginal Atrophy Therapy Market Outlook, By Light Bleeding After Intercourse (2020-2028) (US $MN)
19 Global Vulvar and Vaginal Atrophy Therapy Market Outlook, By Discomfort with Intercourse (2020-2028) (US $MN)
20 Global Vulvar and Vaginal Atrophy Therapy Market Outlook, By Decreased Vaginal Lubrication During Sexual Activity (2020-2028) (US $MN)
21 Global Vulvar and Vaginal Atrophy Therapy Market Outlook, By Shortening and Tightening of the Vaginal Canal (2020-2028) (US $MN)
22 Global Vulvar and Vaginal Atrophy Therapy Market Outlook, By Burning Sensation in the Vagina (2020-2028) (US $MN)
23 Global Vulvar and Vaginal Atrophy Therapy Market Outlook, By Dyspareunia (2020-2028) (US $MN)
24 Global Vulvar and Vaginal Atrophy Therapy Market Outlook, By Urinary Tract Infection (2020-2028) (US $MN)
25 Global Vulvar and Vaginal Atrophy Therapy Market Outlook, By End User (2020-2028) (US $MN)
26 Global Vulvar and Vaginal Atrophy Therapy Market Outlook, By Hospitals (2020-2028) (US $MN)
27 Global Vulvar and Vaginal Atrophy Therapy Market Outlook, By Ambulatory Surgical Centers (2020-2028) (US $MN)
28 Global Vulvar and Vaginal Atrophy Therapy Market Outlook, By Specialty Clinics (2020-2028) (US $MN)
29 North America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Country (2020-2028) (US $MN)
30 North America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Diagnosis (2020-2028) (US $MN)
31 North America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Urine Test (2020-2028) (US $MN)
32 North America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Pelvic Examination (2020-2028) (US $MN)
33 North America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Acid Balance Test (2020-2028) (US $MN)
34 North America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Treatment (2020-2028) (US $MN)
35 North America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Selective Estrogen Receptor Modulators (2020-2028) (US $MN)
36 North America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Non Hormonal Therapy (2020-2028) (US $MN)
37 North America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Laser Therapy (2020-2028) (US $MN)
38 North America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Hormonal Therapy (2020-2028) (US $MN)
39 North America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Indication (2020-2028) (US $MN)
40 North America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Vaginal Dryness (2020-2028) (US $MN)
41 North America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Vaginal Burning (2020-2028) (US $MN)
42 North America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Vaginal Discharge (2020-2028) (US $MN)
43 North America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Genital Itching (2020-2028) (US $MN)
44 North America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Recurrent Urinary Tract Infections (2020-2028) (US $MN)
45 North America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Urinary Incontinence (2020-2028) (US $MN)
46 North America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Light Bleeding After Intercourse (2020-2028) (US $MN)
47 North America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Discomfort with Intercourse (2020-2028) (US $MN)
48 North America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Decreased Vaginal Lubrication During Sexual Activity (2020-2028) (US $MN)
49 North America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Shortening and Tightening of the Vaginal Canal (2020-2028) (US $MN)
50 North America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Burning Sensation in the Vagina (2020-2028) (US $MN)
51 North America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Dyspareunia (2020-2028) (US $MN)
52 North America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Urinary Tract Infection (2020-2028) (US $MN)
53 North America Vulvar and Vaginal Atrophy Therapy Market Outlook, By End User (2020-2028) (US $MN)
54 North America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Hospitals (2020-2028) (US $MN)
55 North America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Ambulatory Surgical Centers (2020-2028) (US $MN)
56 North America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Specialty Clinics (2020-2028) (US $MN)
57 Europe Vulvar and Vaginal Atrophy Therapy Market Outlook, By Country (2020-2028) (US $MN)
58 Europe Vulvar and Vaginal Atrophy Therapy Market Outlook, By Diagnosis (2020-2028) (US $MN)
59 Europe Vulvar and Vaginal Atrophy Therapy Market Outlook, By Urine Test (2020-2028) (US $MN)
60 Europe Vulvar and Vaginal Atrophy Therapy Market Outlook, By Pelvic Examination (2020-2028) (US $MN)
61 Europe Vulvar and Vaginal Atrophy Therapy Market Outlook, By Acid Balance Test (2020-2028) (US $MN)
62 Europe Vulvar and Vaginal Atrophy Therapy Market Outlook, By Treatment (2020-2028) (US $MN)
63 Europe Vulvar and Vaginal Atrophy Therapy Market Outlook, By Selective Estrogen Receptor Modulators (2020-2028) (US $MN)
64 Europe Vulvar and Vaginal Atrophy Therapy Market Outlook, By Non Hormonal Therapy (2020-2028) (US $MN)
65 Europe Vulvar and Vaginal Atrophy Therapy Market Outlook, By Laser Therapy (2020-2028) (US $MN)
66 Europe Vulvar and Vaginal Atrophy Therapy Market Outlook, By Hormonal Therapy (2020-2028) (US $MN)
67 Europe Vulvar and Vaginal Atrophy Therapy Market Outlook, By Indication (2020-2028) (US $MN)
68 Europe Vulvar and Vaginal Atrophy Therapy Market Outlook, By Vaginal Dryness (2020-2028) (US $MN)
69 Europe Vulvar and Vaginal Atrophy Therapy Market Outlook, By Vaginal Burning (2020-2028) (US $MN)
70 Europe Vulvar and Vaginal Atrophy Therapy Market Outlook, By Vaginal Discharge (2020-2028) (US $MN)
71 Europe Vulvar and Vaginal Atrophy Therapy Market Outlook, By Genital Itching (2020-2028) (US $MN)
72 Europe Vulvar and Vaginal Atrophy Therapy Market Outlook, By Recurrent Urinary Tract Infections (2020-2028) (US $MN)
73 Europe Vulvar and Vaginal Atrophy Therapy Market Outlook, By Urinary Incontinence (2020-2028) (US $MN)
74 Europe Vulvar and Vaginal Atrophy Therapy Market Outlook, By Light Bleeding After Intercourse (2020-2028) (US $MN)
75 Europe Vulvar and Vaginal Atrophy Therapy Market Outlook, By Discomfort with Intercourse (2020-2028) (US $MN)
76 Europe Vulvar and Vaginal Atrophy Therapy Market Outlook, By Decreased Vaginal Lubrication During Sexual Activity (2020-2028) (US $MN)
77 Europe Vulvar and Vaginal Atrophy Therapy Market Outlook, By Shortening and Tightening of the Vaginal Canal (2020-2028) (US $MN)
78 Europe Vulvar and Vaginal Atrophy Therapy Market Outlook, By Burning Sensation in the Vagina (2020-2028) (US $MN)
79 Europe Vulvar and Vaginal Atrophy Therapy Market Outlook, By Dyspareunia (2020-2028) (US $MN)
80 Europe Vulvar and Vaginal Atrophy Therapy Market Outlook, By Urinary Tract Infection (2020-2028) (US $MN)
81 Europe Vulvar and Vaginal Atrophy Therapy Market Outlook, By End User (2020-2028) (US $MN)
82 Europe Vulvar and Vaginal Atrophy Therapy Market Outlook, By Hospitals (2020-2028) (US $MN)
83 Europe Vulvar and Vaginal Atrophy Therapy Market Outlook, By Ambulatory Surgical Centers (2020-2028) (US $MN)
84 Europe Vulvar and Vaginal Atrophy Therapy Market Outlook, By Specialty Clinics (2020-2028) (US $MN)
85 Asia Pacific Vulvar and Vaginal Atrophy Therapy Market Outlook, By Country (2020-2028) (US $MN)
86 Asia Pacific Vulvar and Vaginal Atrophy Therapy Market Outlook, By Diagnosis (2020-2028) (US $MN)
87 Asia Pacific Vulvar and Vaginal Atrophy Therapy Market Outlook, By Urine Test (2020-2028) (US $MN)
88 Asia Pacific Vulvar and Vaginal Atrophy Therapy Market Outlook, By Pelvic Examination (2020-2028) (US $MN)
89 Asia Pacific Vulvar and Vaginal Atrophy Therapy Market Outlook, By Acid Balance Test (2020-2028) (US $MN)
90 Asia Pacific Vulvar and Vaginal Atrophy Therapy Market Outlook, By Treatment (2020-2028) (US $MN)
91 Asia Pacific Vulvar and Vaginal Atrophy Therapy Market Outlook, By Selective Estrogen Receptor Modulators (2020-2028) (US $MN)
92 Asia Pacific Vulvar and Vaginal Atrophy Therapy Market Outlook, By Non Hormonal Therapy (2020-2028) (US $MN)
93 Asia Pacific Vulvar and Vaginal Atrophy Therapy Market Outlook, By Laser Therapy (2020-2028) (US $MN)
94 Asia Pacific Vulvar and Vaginal Atrophy Therapy Market Outlook, By Hormonal Therapy (2020-2028) (US $MN)
95 Asia Pacific Vulvar and Vaginal Atrophy Therapy Market Outlook, By Indication (2020-2028) (US $MN)
96 Asia Pacific Vulvar and Vaginal Atrophy Therapy Market Outlook, By Vaginal Dryness (2020-2028) (US $MN)
97 Asia Pacific Vulvar and Vaginal Atrophy Therapy Market Outlook, By Vaginal Burning (2020-2028) (US $MN)
98 Asia Pacific Vulvar and Vaginal Atrophy Therapy Market Outlook, By Vaginal Discharge (2020-2028) (US $MN)
99 Asia Pacific Vulvar and Vaginal Atrophy Therapy Market Outlook, By Genital Itching (2020-2028) (US $MN)
100 Asia Pacific Vulvar and Vaginal Atrophy Therapy Market Outlook, By Recurrent Urinary Tract Infections (2020-2028) (US $MN)
101 Asia Pacific Vulvar and Vaginal Atrophy Therapy Market Outlook, By Urinary Incontinence (2020-2028) (US $MN)
102 Asia Pacific Vulvar and Vaginal Atrophy Therapy Market Outlook, By Light Bleeding After Intercourse (2020-2028) (US $MN)
103 Asia Pacific Vulvar and Vaginal Atrophy Therapy Market Outlook, By Discomfort with Intercourse (2020-2028) (US $MN)
104 Asia Pacific Vulvar and Vaginal Atrophy Therapy Market Outlook, By Decreased Vaginal Lubrication During Sexual Activity (2020-2028) (US $MN)
105 Asia Pacific Vulvar and Vaginal Atrophy Therapy Market Outlook, By Shortening and Tightening of the Vaginal Canal (2020-2028) (US $MN)
106 Asia Pacific Vulvar and Vaginal Atrophy Therapy Market Outlook, By Burning Sensation in the Vagina (2020-2028) (US $MN)
107 Asia Pacific Vulvar and Vaginal Atrophy Therapy Market Outlook, By Dyspareunia (2020-2028) (US $MN)
108 Asia Pacific Vulvar and Vaginal Atrophy Therapy Market Outlook, By Urinary Tract Infection (2020-2028) (US $MN)
109 Asia Pacific Vulvar and Vaginal Atrophy Therapy Market Outlook, By End User (2020-2028) (US $MN)
110 Asia Pacific Vulvar and Vaginal Atrophy Therapy Market Outlook, By Hospitals (2020-2028) (US $MN)
111 Asia Pacific Vulvar and Vaginal Atrophy Therapy Market Outlook, By Ambulatory Surgical Centers (2020-2028) (US $MN)
112 Asia Pacific Vulvar and Vaginal Atrophy Therapy Market Outlook, By Specialty Clinics (2020-2028) (US $MN)
113 South America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Country (2020-2028) (US $MN)
114 South America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Diagnosis (2020-2028) (US $MN)
115 South America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Urine Test (2020-2028) (US $MN)
116 South America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Pelvic Examination (2020-2028) (US $MN)
117 South America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Acid Balance Test (2020-2028) (US $MN)
118 South America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Treatment (2020-2028) (US $MN)
119 South America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Selective Estrogen Receptor Modulators (2020-2028) (US $MN)
120 South America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Non Hormonal Therapy (2020-2028) (US $MN)
121 South America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Laser Therapy (2020-2028) (US $MN)
122 South America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Hormonal Therapy (2020-2028) (US $MN)
123 South America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Indication (2020-2028) (US $MN)
124 South America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Vaginal Dryness (2020-2028) (US $MN)
125 South America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Vaginal Burning (2020-2028) (US $MN)
126 South America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Vaginal Discharge (2020-2028) (US $MN)
127 South America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Genital Itching (2020-2028) (US $MN)
128 South America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Recurrent Urinary Tract Infections (2020-2028) (US $MN)
129 South America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Urinary Incontinence (2020-2028) (US $MN)
130 South America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Light Bleeding After Intercourse (2020-2028) (US $MN)
131 South America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Discomfort with Intercourse (2020-2028) (US $MN)
132 South America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Decreased Vaginal Lubrication During Sexual Activity (2020-2028) (US $MN)
133 South America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Shortening and Tightening of the Vaginal Canal (2020-2028) (US $MN)
134 South America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Burning Sensation in the Vagina (2020-2028) (US $MN)
135 South America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Dyspareunia (2020-2028) (US $MN)
136 South America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Urinary Tract Infection (2020-2028) (US $MN)
137 South America Vulvar and Vaginal Atrophy Therapy Market Outlook, By End User (2020-2028) (US $MN)
138 South America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Hospitals (2020-2028) (US $MN)
139 South America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Ambulatory Surgical Centers (2020-2028) (US $MN)
140 South America Vulvar and Vaginal Atrophy Therapy Market Outlook, By Specialty Clinics (2020-2028) (US $MN)
141 Middle East & Africa Vulvar and Vaginal Atrophy Therapy Market Outlook, By Country (2020-2028) (US $MN)
142 Middle East & Africa Vulvar and Vaginal Atrophy Therapy Market Outlook, By Diagnosis (2020-2028) (US $MN)
143 Middle East & Africa Vulvar and Vaginal Atrophy Therapy Market Outlook, By Urine Test (2020-2028) (US $MN)
144 Middle East & Africa Vulvar and Vaginal Atrophy Therapy Market Outlook, By Pelvic Examination (2020-2028) (US $MN)
145 Middle East & Africa Vulvar and Vaginal Atrophy Therapy Market Outlook, By Acid Balance Test (2020-2028) (US $MN)
146 Middle East & Africa Vulvar and Vaginal Atrophy Therapy Market Outlook, By Treatment (2020-2028) (US $MN)
147 Middle East & Africa Vulvar and Vaginal Atrophy Therapy Market Outlook, By Selective Estrogen Receptor Modulators (2020-2028) (US $MN)
148 Middle East & Africa Vulvar and Vaginal Atrophy Therapy Market Outlook, By Non Hormonal Therapy (2020-2028) (US $MN)
149 Middle East & Africa Vulvar and Vaginal Atrophy Therapy Market Outlook, By Laser Therapy (2020-2028) (US $MN)
150 Middle East & Africa Vulvar and Vaginal Atrophy Therapy Market Outlook, By Hormonal Therapy (2020-2028) (US $MN)
151 Middle East & Africa Vulvar and Vaginal Atrophy Therapy Market Outlook, By Indication (2020-2028) (US $MN)
152 Middle East & Africa Vulvar and Vaginal Atrophy Therapy Market Outlook, By Vaginal Dryness (2020-2028) (US $MN)
153 Middle East & Africa Vulvar and Vaginal Atrophy Therapy Market Outlook, By Vaginal Burning (2020-2028) (US $MN)
154 Middle East & Africa Vulvar and Vaginal Atrophy Therapy Market Outlook, By Vaginal Discharge (2020-2028) (US $MN)
155 Middle East & Africa Vulvar and Vaginal Atrophy Therapy Market Outlook, By Genital Itching (2020-2028) (US $MN)
156 Middle East & Africa Vulvar and Vaginal Atrophy Therapy Market Outlook, By Recurrent Urinary Tract Infections (2020-2028) (US $MN)
157 Middle East & Africa Vulvar and Vaginal Atrophy Therapy Market Outlook, By Urinary Incontinence (2020-2028) (US $MN)
158 Middle East & Africa Vulvar and Vaginal Atrophy Therapy Market Outlook, By Light Bleeding After Intercourse (2020-2028) (US $MN)
159 Middle East & Africa Vulvar and Vaginal Atrophy Therapy Market Outlook, By Discomfort with Intercourse (2020-2028) (US $MN)
160 Middle East & Africa Vulvar and Vaginal Atrophy Therapy Market Outlook, By Decreased Vaginal Lubrication During Sexual Activity (2020-2028) (US $MN)
161 Middle East & Africa Vulvar and Vaginal Atrophy Therapy Market Outlook, By Shortening and Tightening of the Vaginal Canal (2020-2028) (US $MN)
162 Middle East & Africa Vulvar and Vaginal Atrophy Therapy Market Outlook, By Burning Sensation in the Vagina (2020-2028) (US $MN)
163 Middle East & Africa Vulvar and Vaginal Atrophy Therapy Market Outlook, By Dyspareunia (2020-2028) (US $MN)
164 Middle East & Africa Vulvar and Vaginal Atrophy Therapy Market Outlook, By Urinary Tract Infection (2020-2028) (US $MN)
165 Middle East & Africa Vulvar and Vaginal Atrophy Therapy Market Outlook, By End User (2020-2028) (US $MN)
166 Middle East & Africa Vulvar and Vaginal Atrophy Therapy Market Outlook, By Hospitals (2020-2028) (US $MN)
167 Middle East & Africa Vulvar and Vaginal Atrophy Therapy Market Outlook, By Ambulatory Surgical Centers (2020-2028) (US $MN)
168 Middle East & Africa Vulvar and Vaginal Atrophy Therapy Market Outlook, By Specialty Clinics (2020-2028) (US $MN)

Frequently Asked Questions

In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929

Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.

Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.

All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929

We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.

We have 3 different licensing options available in electronic format.

  • Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
  • 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
  • Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.

All our reports are typically be emailed to you as an attachment.

To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.

We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.

Request Customization

We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.

Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.

WHY CHOOSE US ?

Assured Quality

Assured Quality

Best in class reports with high standard of research integrity

24X7 Research Support

24X7 Research Support

Continuous support to ensure the best customer experience.

Free Customization

Free Customization

Adding more values to your product of interest.

Safe and Secure Access

Safe & Secure Access

Providing a secured environment for all online transactions.

Trusted by 600+ Brands

Trusted by 600+ Brands

Serving the most reputed brands across the world.

Testimonials